News headlines about VBI Vaccines (NASDAQ:VBIV) have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.1621332802117 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
VBI Vaccines (NASDAQ:VBIV) traded down $0.10 during trading on Wednesday, reaching $3.66. The company had a trading volume of 101,035 shares, compared to its average volume of 110,268. VBI Vaccines has a 1 year low of $3.04 and a 1 year high of $6.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.03 and a quick ratio of 0.97.
VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.15 million. VBI Vaccines had a negative return on equity of 49.17% and a negative net margin of 4,463.06%. sell-side analysts forecast that VBI Vaccines will post -0.9 earnings per share for the current year.
VBIV has been the subject of a number of recent analyst reports. BidaskClub downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. BMO Capital Markets initiated coverage on VBI Vaccines in a research note on Wednesday, November 15th. They set an “outperform” rating and a $11.00 price target for the company. Finally, Canaccord Genuity initiated coverage on VBI Vaccines in a research note on Wednesday, November 1st. They set a “buy” rating and a $10.00 price target for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $8.75.
In other VBI Vaccines news, CEO Jeff Baxter purchased 15,000 shares of the stock in a transaction on Tuesday, November 28th. The stock was bought at an average price of $4.75 per share, for a total transaction of $71,250.00. Following the acquisition, the chief executive officer now directly owns 135,255 shares of the company’s stock, valued at $642,461.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 34.10% of the company’s stock.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/favorable-news-coverage-somewhat-unlikely-to-affect-vbi-vaccines-vbiv-stock-price-2.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.